| Title |
Phase II study of darinaparsin in patients with advanced hepatocellular carcinoma
|
|---|---|
| Published in |
Investigational New Drugs, June 2009
|
| DOI | 10.1007/s10637-009-9286-9 |
| Pubmed ID | |
| Authors |
Jennifer Wu, Charles Henderson, Lynn Feun, Peter Van Veldhuizen, Philip Gold, Hui Zheng, Theresa Ryan, Lawrence S. Blaszkowsky, HaoBin Chen, Max Costa, Barry Rosenzweig, MaryLynn Nierodzik, Howard Hochster, Franco Muggia, Giovanni Abbadessa, Jonathan Lewis, Andrew X. Zhu |
| Abstract |
Darinaparsin is a novel organic arsenic that reaches higher intracellular concentration with decreased toxicity compared to inorganic arsenic. We conducted a multi-center phase II study with darinaparsin in patients with advanced HCC. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 2 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 30 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 30 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 5 | 17% |
| Researcher | 5 | 17% |
| Other | 3 | 10% |
| Student > Bachelor | 3 | 10% |
| Professor > Associate Professor | 3 | 10% |
| Other | 3 | 10% |
| Unknown | 8 | 27% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 7 | 23% |
| Nursing and Health Professions | 3 | 10% |
| Agricultural and Biological Sciences | 3 | 10% |
| Biochemistry, Genetics and Molecular Biology | 2 | 7% |
| Psychology | 2 | 7% |
| Other | 3 | 10% |
| Unknown | 10 | 33% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 16 August 2018.
All research outputs
#14,198,374
of 22,759,618 outputs
Outputs from Investigational New Drugs
#699
of 1,168 outputs
Outputs of similar age
#91,035
of 109,230 outputs
Outputs of similar age from Investigational New Drugs
#8
of 10 outputs
Altmetric has tracked 22,759,618 research outputs across all sources so far. This one is in the 35th percentile – i.e., 35% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,168 research outputs from this source. They receive a mean Attention Score of 4.7. This one is in the 37th percentile – i.e., 37% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 109,230 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 15th percentile – i.e., 15% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 10 others from the same source and published within six weeks on either side of this one. This one has scored higher than 2 of them.